- August 17, 2026
- By Dr. Sarah Thompson, PharmD
Fluconazole is a systemically absorbed triazole antifungal medicine used against susceptible Candida and Cryptococcus infections by interfering with fungal membrane formation, and its Canadian access rules are unusual because a single 150 mg oral dose intended specifically for vaginal candidiasis can be sold without a prescription, while other strengths, repeated courses and systemic treatment remain within the prescription-drug system and may involve substantially different doses, monitoring requirements and pharmacy costs. Health Canada currently lists marketed fluconazole products in several strengths, including non-prescription 150 mg capsules and prescription 50 mg and 100 mg products.
| Active ingredient | Fluconazole |
| Well-known brand | Diflucan |
| Drug class | Triazole antifungal |
| 150 mg vaginal-candidiasis product | Available without prescription under defined conditions |
| Other oral strengths | Generally prescription |
| Common prescription strengths | 50 mg and 100 mg tablets |
| Single-dose product | 150 mg capsule |
| Other forms | Oral suspension and intravenous solution |
| Main organisms | Susceptible Candida species and Cryptococcus |
| Common non-prescription use | Vaginal yeast infection |
| Prescription uses | Oral, esophageal and systemic candidiasis, cryptococcal meningitis and selected prophylactic uses |
| Important dose-adjustment issue | Kidney function |
| Important interaction mechanism | CYP2C9, CYP2C19 and CYP3A4 inhibition |
Availability in Canadian Market
Fluconazole is readily represented in the Canadian drug market, although its legal status depends on the strength, package and indication. Health Canada’s Drug Product Database contains marketed prescription products in 50 mg and 100 mg strengths from manufacturers including Apotex, Pharmascience, Sanis and Sivem, while Pfizer’s Diflucan oral suspension and intravenous formulation also remain marketed.
The situation is different for the familiar 150 mg capsule used for vaginal yeast infections. Health Canada lists Diflucan One 150 mg as a marketed non-prescription product, and multiple other manufacturers currently market their own 150 mg fluconazole capsules under the same federal non-prescription classification.
This creates two distinct purchasing routes:
| Product situation | Typical Canadian access |
|---|---|
| Fluconazole 150 mg, one oral dosage unit for vaginal candidiasis | Non-prescription under the defined exemption |
| Fluconazole 50 mg | Prescription |
| Fluconazole 100 mg | Prescription |
| Longer systemic oral treatment | Prescription |
| Diflucan oral suspension | Prescription |
| Intravenous fluconazole | Prescription |
The distinction is clinically important because a patient cannot assume that every fluconazole product becomes non-prescription simply because Diflucan One can be purchased without a prescription. NAPRA places fluconazole in Schedule I except for the specific 150 mg vaginal-candidiasis presentation.
Brand availability also differs from active-ingredient availability. Health Canada currently lists several marketed fluconazole products even though some older Diflucan tablet entries have been cancelled after marketing. A prescription written for fluconazole can therefore be filled with an authorized product that does not carry the Pfizer brand name.
Patients trying to locate a particular prescription strength may also need to distinguish authorization from local inventory. A product can remain marketed nationally while an individual pharmacy needs to obtain it from its wholesaler.
Why the 150 mg Capsule Has Different Pharmacy Status?
Canada makes a narrow exception for one particular use of oral fluconazole. The federal Prescription Drug List excludes fluconazole when it is supplied as 150 mg per oral dosage unit and indicated for vaginal candidiasis. Health Canada separately confirms that non-prescription oral 150 mg products are authorized for single-dose treatment of vaginal yeast infections.
NAPRA classifies this presentation as Schedule III when the package contains no more than 150 mg of fluconazole. Schedule III medicines can be selected without a prescription from the professional-services area of a pharmacy, where a pharmacist remains available to assist with selection. Provincial and territorial implementation can differ, and Quebec uses its own scheduling framework.
The exception is narrow in three ways:
- the oral dosage unit contains 150 mg;
- the indication is vaginal candidiasis;
- the package contains no more than 150 mg of fluconazole.
A bottle containing multiple 150 mg capsules for recurrent therapy is therefore not equivalent to the one-capsule non-prescription presentation simply because the strength printed on each capsule is identical.
The purpose of this distinction becomes easier to understand when the treatment regimens are compared. Uncomplicated vaginal candidiasis can be treated with one 150 mg oral dose, while oral thrush, esophageal candidiasis, systemic Candida infections and cryptococcal meningitis require different doses and can continue for weeks. Pfizer’s July 2026 Canadian Diflucan monograph describes 100 mg daily for at least two weeks for oropharyngeal candidiasis, 100–200 mg daily for esophageal disease and 200–400 mg daily for serious systemic candidiasis.
A non-prescription package should consequently not become the basis for constructing a prescription-strength regimen by buying several individual 150 mg capsules.
Self-selection also becomes less appropriate when the diagnosis is uncertain. Vaginal itching, burning and discharge can occur with candidiasis, bacterial vaginosis, sexually transmitted infections, irritation and other gynecologic conditions. Repeatedly buying another single-dose capsule for recurrent symptoms can delay identification of another cause.
Typical Fluconazole Prices and Treatment Costs
Fluconazole pricing varies sharply according to strength, brand, prescription status and where the price is measured.
Ontario’s current Drug Benefit Formulary provides a useful reference for prescription ingredient costs. Interchangeable 50 mg fluconazole tablets are listed at C$1.2904 per tablet and 100 mg products at C$2.2891 per tablet. Several interchangeable 150 mg capsules are listed at C$3.9424 per capsule.
The branded 150 mg Diflucan formulary entry is substantially more expensive at C$15.65 per capsule, while the amount listed for reimbursement is C$3.9424, matching the interchangeable product price.
| Product example | Ontario formulary unit price |
|---|---|
| Fluconazole 50 mg tablet | C$1.2904 |
| Fluconazole 100 mg tablet | C$2.2891 |
| Interchangeable fluconazole 150 mg capsule | C$3.9424 |
| Branded Diflucan 150 mg entry | C$15.65 |
These figures are drug-benefit or unit prices rather than guaranteed totals at a retail pharmacy. Dispensing fees, plan eligibility, deductibles and pharmacy pricing can change what a patient actually pays.
Non-prescription retail pricing follows a different pattern. Current Canadian online listings provide concrete examples. Well.ca lists a one-capsule Option+ Fluconazole 150 mg product at C$14.48 and CanesOral 150 mg at C$23.98. A combination package containing oral fluconazole 150 mg plus 2% clotrimazole cream is listed at C$27.48.
This means that the ingredient cost recorded in a provincial formulary can be only a fraction of the shelf price of a packaged non-prescription product.
Prescription treatment also becomes more expensive as duration increases. A patient receiving 100 mg every day for several weeks uses a fundamentally different quantity from someone purchasing a single 150 mg vaginal-candidiasis capsule.
Useful price comparisons should therefore identify:
- exact strength;
- number of tablets or capsules;
- prescription or non-prescription status;
- manufacturer;
- brand or non-brand product;
- dispensing fee;
- shipping fee when ordered online;
- currency;
- public or private insurance reimbursement.
Comparing only “price per pill” can be especially misleading when one product is intended as a complete single-dose course and another is one unit from a treatment lasting several weeks.
Public and Private Coverage
Provincial drug plans determine their own reimbursement rules, so fluconazole coverage cannot be described accurately with one national answer.
Ontario currently lists multiple 50 mg and 100 mg fluconazole products as benefits without a Limited Use designation on the formulary entries. The 150 mg capsule follows different rules.
For fluconazole 150 mg, Ontario uses Limited Use criteria specifically for vaginal candidiasis. The formulary identifies a 150 mg oral dose for one day and states that repeats within a 25-day period will not be reimbursed under that authorization.
That rule produces an important difference between availability and coverage. A woman can purchase an eligible 150 mg vaginal-candidiasis product without a prescription, yet public reimbursement operates according to separate provincial eligibility and formulary rules.
Private insurance introduces another layer. Plans can differ in:
- whether a non-prescription product is reimbursed;
- whether a prescription is required for reimbursement even when the product can legally be purchased without one;
- brand-name versus interchangeable-product reimbursement;
- deductibles;
- copayments;
- annual drug limits.
The branded and interchangeable 150 mg Ontario entries demonstrate the importance of brand reimbursement. The formulary lists C$15.65 as the unit price of the branded Diflucan entry but C$3.9424 as the amount the ministry pays, corresponding to the interchangeable-product level.
Patients checking insurance can provide the exact product name and DIN instead of asking only whether “Diflucan” is covered. Different manufacturers have separate DINs even when they contain the same active ingredient and strength.
Coverage becomes more consequential during prolonged therapy. A one-capsule treatment creates a modest one-time medication expense, while several weeks or months of fluconazole for a serious infection can involve substantially more medication and monitoring.
Getting Diflucan Prescription Online
Fluconazole can be purchased or dispensed online in Canada, but the process depends on which formulation is being ordered.
A single 150 mg non-prescription product for vaginal candidiasis can appear in the ordinary online health section of a Canadian retailer. Well.ca currently sells one-capsule fluconazole products and states that its CanesOral 150 mg product can be shipped only to Canadian customers.
Prescription fluconazole is different. A 50 mg or 100 mg course, oral suspension or another prescription regimen requires the normal pharmacy dispensing process even when the transaction starts online.
Patients using a Canadian online pharmacy should establish:
- the legal name of the dispensing pharmacy;
- its Canadian address;
- the province or territory where it operates;
- the pharmacy regulator responsible for that location;
- whether the product requires a prescription;
- strength and dosage form;
- manufacturer;
- DIN when applicable;
- number of doses;
- total cost including shipping;
- whether a pharmacist is available for consultation.
NAPRA advises consumers to verify online pharmacies through the pharmacy regulatory authority in the province or territory where the business is established. A Canadian website name or maple-leaf branding is not a substitute for licensing verification.
Another distinction concerns domestic sales versus importation. A Canadian resident buying a non-prescription fluconazole product from a Canadian retailer is in a different regulatory situation from someone ordering prescription fluconazole from an overseas seller.
Health Canada’s July 2026 personal-importation guidance states that Canadian residents are generally not permitted to import prescription drugs by mail or courier, apart from specified exemptions.
Patients should also verify whether an international pharmacy listing actually represents a Canadian-manufactured or Canadian-dispensed product. The country where the website operator is located, the country where the medicine was manufactured and the country from which the package ships can all be different.
Canadian Orders for U.S. Patients
A U.S. patient can encounter Canadian fluconazole listings for several reasons, including price comparison, access to Diflucan-branded products or the Canadian non-prescription status of the 150 mg vaginal-candidiasis package. The Canadian classification does not determine U.S. import law.
FDA guidance states that U.S. citizens are, in most circumstances, prohibited from importing foreign drug products for personal use when the products do not comply with U.S. approval requirements. FDA personnel can consider enforcement discretion in defined situations, but the criteria do not amount to a general right to order a three-month supply from a foreign pharmacy.
The often-quoted “90-day” or “three-month” rule is therefore easy to misunderstand. For U.S. citizens, the FDA lists a quantity generally no greater than three months as only one element of its personal-importation considerations. Other conditions can include a serious condition for which effective domestic treatment may be unavailable, absence of unreasonable risk, personal-use affirmation and information about the physician responsible for treatment.
Fluconazole is already available through U.S. prescription channels, which makes the regulatory situation different from importing a drug with no effective domestic alternative.
The Canadian 150 mg exception creates another possible source of confusion. A product can be legally sold without a prescription under Canadian rules while still entering the United States as a foreign drug shipment subject to U.S. federal requirements.
A cross-border order therefore involves separate questions:
- Can the Canadian seller legally supply the product?
- Does that formulation require a prescription where it is dispensed?
- Where is the medicine actually manufactured and shipped from?
- Does the shipment comply with U.S. import requirements?
A successful website checkout answers only the first stages of that process.
For U.S. patients comparing costs, a domestic fluconazole prescription may also be inexpensive because fluconazole is available from multiple manufacturers. The final comparison should include prescription cost, pharmacy fees, shipping, delivery time and the legal status of the shipment instead of looking only at the advertised Canadian price.
Which Fungal Infections Respond to Diflucan?
Fluconazole is an antifungal medicine, not a general treatment for any condition described as an “infection.”
Pfizer’s current Canadian Diflucan monograph lists treatment of oropharyngeal and esophageal candidiasis, serious systemic Candida infections including candidal urinary tract infection, peritonitis and pneumonia, and cryptococcal meningitis. It also includes prevention of recurrent cryptococcal meningitis in patients with AIDS and prophylaxis of candidiasis in selected patients undergoing bone marrow transplantation with chemotherapy and/or radiation treatment.
The familiar non-prescription 150 mg capsule has a much narrower purpose: treatment of vaginal candidiasis, commonly called a vaginal yeast infection. Health Canada authorizes the single oral 150 mg presentation for this indication.
The conditions can therefore be grouped broadly as:
- vaginal candidiasis;
- oral candidiasis or thrush;
- esophageal candidiasis;
- serious systemic Candida infection;
- cryptococcal meningitis;
- prevention of selected Candida infections in high-risk patients;
- prevention of cryptococcal meningitis recurrence in specified patients.
The site of infection matters because Candida found on a mucosal surface and Candida circulating in the bloodstream are clinically very different problems.
Fluconazole also does not cover every Candida species equally well. Pfizer’s current Canadian monograph states that Candida glabrata can have reduced susceptibility, while Candida krusei is intrinsically resistant and Candida auris frequently shows resistance. Treatment failure involving these organisms can require another antifungal.
This becomes relevant in recurrent vaginal symptoms as well. Repeated symptoms after a 150 mg dose can result from resistant or less-susceptible yeast, but recurrence can also represent reinfection, another Candida species or a condition that was never candidiasis in the first place.
Fluconazole should not be expected to treat bacterial vaginosis, trichomoniasis, urinary infections caused by ordinary bacteria or viral infections merely because some symptoms overlap.
Oral, Liquid and Intravenous Fluconazole Options
The Canadian fluconazole market contains several formulations intended for very different settings.
Current Health Canada records show marketed prescription tablets in 50 mg and 100 mg strengths, while multiple manufacturers sell non-prescription 150 mg capsules for vaginal candidiasis. Pfizer’s current Diflucan monograph covers an oral suspension containing 50 mg per 5 mL after reconstitution and an intravenous solution containing 2 mg/mL.
| Dosage form | Example strength | Typical role |
|---|---|---|
| Oral tablet | 50 mg | Prescription systemic treatment |
| Oral tablet | 100 mg | Prescription systemic treatment |
| Oral capsule | 150 mg | Single-dose vaginal-candidiasis treatment under defined conditions |
| Oral suspension | 50 mg/5 mL | Prescription treatment when liquid dosing is appropriate |
| Intravenous solution | 2 mg/mL | Hospital or other supervised systemic treatment |
The oral suspension is not simply a liquid version intended for anyone who prefers liquid medicine. Pfizer’s 2026 monograph specifies a final concentration of 10 mg/mL after reconstitution, equivalent to 50 mg per 5 mL, and the required volume depends on the prescribed dose.
A 150 mg capsule also has a specific role. It should not be treated as a convenient substitute for three 50 mg tablets or as a building block for a prolonged regimen without prescription instructions.
This matters because prescription treatment frequently uses daily doses such as 100 mg, 200 mg or 400 mg. The pharmacy may use combinations of available strengths or a liquid formulation to achieve the prescribed amount.
Oral fluconazole has high systemic availability. Pfizer reports oral bioavailability above 90%, with peak concentrations generally reached within approximately two hours and a terminal plasma half-life of about 30 hours. Oral and intravenous daily doses can therefore be equivalent when the patient is able to absorb oral treatment.
The long half-life also helps explain why a single 150 mg capsule can continue exerting antifungal activity for several days after administration.
Dosing Patterns From Single-Dose to Long-Term Therapy
Fluconazole dosing ranges from one capsule taken once to daily treatment lasting many weeks, so the indication should always be identified before a dose is interpreted.
For non-prescription treatment of vaginal candidiasis, the Canadian product is supplied as one 150 mg oral capsule taken as a single dose. Health Canada describes this formulation as a single-dose treatment.
Prescription systemic regimens are very different.
| Condition | Example regimen from Canadian Diflucan information |
|---|---|
| Oropharyngeal candidiasis | 100 mg once daily for at least 2 weeks |
| Esophageal candidiasis | 100–200 mg once daily for at least 3 weeks and at least 2 weeks after symptom resolution |
| Systemic candidiasis | 200–400 mg once daily for at least 4 weeks and at least 2 weeks after symptoms resolve |
| Cryptococcal meningitis | 200–400 mg once daily, with prolonged initial treatment |
| Prevention of recurrence of cryptococcal meningitis in AIDS | 200 mg once daily |
| Bone marrow transplant prophylaxis | 400 mg once daily in the specified high-risk setting |
These are examples from the Canadian Diflucan monograph and are not dosing instructions for an undiagnosed infection. Serious fungal disease is managed according to organism, laboratory findings, response and patient-specific factors.
Fluconazole can generally be taken without coordinating the dose with meals because oral absorption is high and food does not create the same absorption problem seen with some other antifungal agents.
Kidney function is particularly important during repeated dosing. Fluconazole is cleared predominantly through renal excretion as unchanged drug. Pfizer’s Canadian monograph recommends full dosing when creatinine clearance exceeds 50 mL/min and reduced maintenance dosing at lower levels, with specific provisions for hemodialysis.
A missed dose during a multi-day regimen should be taken when remembered unless the next dose is approaching. The Canadian monograph specifically advises against doubling the next dose.
A single vaginal-candidiasis capsule follows a different situation because there is no next daily dose in the standard one-dose course.
Common Reactions and More Serious Safety Concerns
Fluconazole is often tolerated without major difficulty, particularly when exposure consists of one 150 mg capsule, but the safety profile becomes more significant during prolonged or high-dose systemic treatment.
In clinical trials of patients receiving fluconazole for seven days or longer, commonly reported treatment-related effects included nausea, headache, skin rash, abdominal pain, vomiting and diarrhea. Liver-enzyme elevations were also observed.
For the single 150 mg dose studied for vaginal candidiasis, the Canadian Diflucan monograph reports headache, nausea and abdominal pain as the most frequent treatment-related complaints, with diarrhea, dyspepsia, dizziness and taste disturbance reported less often. Most were mild to moderate.
Commonly reported effects include:
- headache;
- nausea;
- abdominal discomfort;
- diarrhea;
- vomiting;
- dizziness;
- indigestion;
- altered taste;
- rash.
More significant reactions require a different response.
Fluconazole has rarely been associated with serious hepatic injury. Pfizer’s current monograph describes reactions ranging from abnormal liver tests to hepatitis, hepatic necrosis and hepatic failure. Patients who develop evidence of worsening liver injury during treatment require clinical assessment.
Severe skin reactions have also been reported, including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS. Progressive widespread rash, blistering, skin peeling or systemic illness accompanying a rash deserves prompt medical attention.
Cardiac rhythm is another important consideration. Fluconazole can prolong the QT interval, and very rare cases of torsade de pointes have occurred, particularly in patients with other risk factors such as structural heart disease, electrolyte abnormalities or interacting medicines.
Patients who need additional assessment before or during treatment include those with significant kidney impairment, liver disease, known rhythm problems, low potassium levels, previous serious azole reactions or extensive interacting medication use.
Pregnancy deserves particular attention. The current Canadian prescription Diflucan monograph advises against use during pregnancy except for severe or potentially life-threatening fungal infections when the expected benefit justifies the potential fetal risk. Reports and observational studies have raised concern about pregnancy outcomes even after exposures beginning at 150 mg, while prolonged doses of 400–800 mg daily during the first trimester have been associated with a distinctive pattern of congenital abnormalities.
Medication Interactions That Can Change Treatment
Drug interactions are one of the areas where a seemingly simple antifungal prescription can become clinically important.
Fluconazole inhibits several cytochrome P450 enzymes. Pfizer’s current monograph describes it as a moderate inhibitor of CYP2C9 and CYP3A4 and a strong inhibitor of CYP2C19. Its enzyme-inhibiting effect can persist for approximately four to five days after treatment is stopped because fluconazole has a long half-life.
This means that interaction risk does not disappear immediately after the final tablet.
Examples include:
| Medicine or group | Main issue |
|---|---|
| Warfarin and related anticoagulants | Increased anticoagulant effect and bleeding risk |
| Cyclosporine | Increased cyclosporine exposure |
| Tacrolimus | Increased exposure and toxicity risk |
| Phenytoin | Increased phenytoin concentrations |
| Sulfonylurea diabetes medicines | Increased exposure and hypoglycemia risk |
| Certain statins | Increased statin exposure and muscle toxicity risk |
| Amiodarone and other QT-prolonging drugs | Greater cardiac rhythm concern |
| Some benzodiazepines | Increased sedative exposure |
| Rifampin | Can alter fluconazole exposure |
| Voriconazole | Concomitant administration is not recommended |
Warfarin is particularly important because concurrent fluconazole can increase prothrombin-time response. Canadian prescribing information recommends careful monitoring when fluconazole is used with coumarin-type anticoagulants.
Certain QT-prolonging combinations are contraindicated. The current monograph specifically identifies drugs including erythromycin, pimozide and quinidine in this context.
A complete medication review therefore matters even before a short course. The list should include:
- prescription medicines;
- over-the-counter drugs;
- cardiovascular medicines;
- anticoagulants;
- diabetes medicines;
- antiseizure therapy;
- immunosuppressants;
- psychiatric medicines;
- supplements and natural products.
The interaction issue also explains why buying multiple 150 mg non-prescription capsules and constructing a longer course independently is different from taking the authorized single dose.
Kidney function adds another layer. Because fluconazole is predominantly eliminated through the kidneys, repeated prescription dosing may require adjustment when renal clearance is reduced.
Fluconazole Alternatives
Fluconazole is only one antifungal option. The appropriate alternative depends on the organism, infection site, severity, pregnancy status, previous treatment and susceptibility of the fungus.
For uncomplicated vaginal candidiasis, local azole therapy provides an important alternative to oral treatment. Canadian products use agents such as clotrimazole and miconazole, and some non-prescription combination packages pair a 150 mg fluconazole capsule with an external clotrimazole cream.
Systemic fungal disease requires a much broader comparison. Other azole antifungals, echinocandins and amphotericin formulations can be used in appropriate settings, but they are not direct milligram-for-milligram substitutes for fluconazole.
The organism can make the decision for the prescriber. Candida glabrata has reduced fluconazole susceptibility, Candida krusei is intrinsically resistant and Candida auris frequently demonstrates resistance, so persistent or serious infection may require culture, susceptibility testing and another antifungal strategy.
Common Patient Questions
Is Diflucan the Same as Fluconazole?
Fluconazole is the active medicinal ingredient. Diflucan is Pfizer’s established brand name for fluconazole products. Canadian pharmacies and retailers also supply products from other manufacturers, so the package may say fluconazole without the Diflucan name while containing the same active ingredient.
Is Fluconazole an Antibiotic?
Fluconazole is an antifungal, not an antibacterial antibiotic. It acts against susceptible fungi and yeasts and does not treat ordinary bacterial infections.
This distinction matters with vaginal symptoms because bacterial vaginosis and vaginal candidiasis can cause overlapping complaints but require different treatments.
Can You Buy Diflucan Without a Prescription?
The answer depends on the formulation. In Canada, a 150 mg oral dosage unit indicated for vaginal candidiasis and supplied in a package containing no more than 150 mg is non-prescription. Other fluconazole uses remain prescription treatment.
Does One 150 mg Capsule Treat Every Yeast Infection?
No. The single 150 mg regimen is associated with vaginal candidiasis. Oral candidiasis, esophageal infection, systemic candidiasis and cryptococcal meningitis use different doses and much longer courses.
The term “yeast infection” therefore does not identify a dose on its own.
How Quickly Does Fluconazole Work for a Vaginal Yeast Infection?
Canadian retail information for Diflucan One describes symptom improvement beginning within approximately 24 hours, while complete symptom resolution can take several days. Walmart Canada’s current Diflucan One information advises medical follow-up if symptoms have not improved within three days or have not resolved within seven days.
A lack of immediate relief on the evening after taking the capsule is therefore not evidence that the dose failed.
What If the Infection Keeps Coming Back?
Repeated vaginal symptoms should not automatically lead to repeated single-dose treatment. Recurrence can involve another Candida species, reduced fluconazole susceptibility, another vaginal condition or a factor that increases the likelihood of candidiasis.
The Canadian Diflucan monograph specifically warns that Candida species other than C. albicans can have reduced susceptibility or resistance to fluconazole.
Can Fluconazole Treat a UTI?
Fluconazole can be used for selected urinary tract infections caused by susceptible Candida, and candidal urinary tract infection appears among the serious systemic Candida indications in the Canadian Diflucan monograph.
That is very different from an ordinary bacterial UTI. Most common urinary infections are bacterial and require antibacterial treatment rather than fluconazole.
Can It Treat Oral Thrush?
Yes. Oropharyngeal candidiasis is an established prescription indication. The current Canadian Diflucan monograph uses 100 mg once daily for at least two weeks as its adult treatment guideline.
A one-time 150 mg vaginal-candidiasis capsule should not be assumed to be the appropriate oral-thrush regimen.
Can Fluconazole Treat Ringworm or Athlete’s Foot?
Fluconazole has antifungal activity beyond Candida, but common superficial dermatophyte infections are frequently treated with topical antifungal products or other selected systemic agents depending on the site and severity.
Using a leftover fluconazole capsule for a new skin rash is therefore inappropriate without establishing whether the rash is fungal and whether oral therapy is warranted.
Can Fluconazole Be Taken During Pregnancy?
Pregnancy changes the risk assessment substantially. Pfizer’s current Canadian prescription monograph advises against fluconazole in pregnancy except when a severe or potentially life-threatening fungal infection makes treatment necessary after weighing the potential fetal risk.
A patient who is pregnant or may be pregnant should therefore seek professional guidance instead of automatically selecting the non-prescription 150 mg capsule.
Is Fluconazole Safe With Kidney Disease?
Fluconazole is cleared primarily through the kidneys, so renal function can materially affect repeated dosing. The Canadian monograph provides reduced maintenance doses for patients with lower creatinine clearance and separate instructions for hemodialysis.
A single non-prescription dose and a multi-week systemic regimen consequently create different dosing considerations.
Can Alcohol Be Used With Fluconazole?
Fluconazole does not carry the same characteristic alcohol prohibition associated with metronidazole. The more important medication-specific concerns are liver function, interacting drugs and the condition being treated.
Heavy alcohol use can still matter clinically when liver disease or abnormal liver tests are present because serious hepatic reactions, although uncommon, have been reported with fluconazole.
Why Might Another Antifungal Be Chosen Instead?
Another agent may be selected because the organism is resistant, the infection is located where another medicine has stronger evidence, the patient has a clinically important drug interaction, pregnancy changes the preferred treatment, or previous fluconazole therapy did not work.
Resistance is especially relevant with Candida krusei, Candida auris and some Candida glabrata infections.
Can Leftover Fluconazole Be Saved for the Next Infection?
A remaining prescription tablet should not be treated as a universal antifungal supply. Fluconazole regimens vary from a single 150 mg dose to hundreds of milligrams daily for several weeks, and the next episode may involve another organism or a condition that is not fungal.
Using the correct diagnosis and regimen is more important than having the same active ingredient available at home.